During the last few decades, the treatment of HIV-infected patients by highly active antiretroviral therapy, including protease inhibitors (PIs), has become standard. Here, we present results of analysis of a patient-derived, multiresistant HIV-1 CRF02_AG recombinant strain with a highly mutated protease (PR) coding sequence, where up to 19 coding mutations have accumulated in the PR. The results of biochemical analysis in vitro showed that the patient-derived PR is highly resistant to most of the currently used PIs and that it also exhibits very poor catalytic activity. Determination of the crystal structure revealed prominent changes in the flap elbow region and S1/S1' active site subsites. While viral loads in the patient were found to be high, the insertion of the patient-derived PR into a HIV-1 subtype B backbone resulted in reduction of infectivity by 3 orders of magnitude. Fitness compensation was not achieved by elevated polymerase (Pol) expression, but the introduction of patient-derived gag and pol sequences in a CRF02_AG backbone rescued viral infectivity to near wild-type (wt) levels. The mutations that accumulated in the vicinity of the processing sites spanning the p2/NC, NC/p1, and p6pol/PR proteins lead to much more efficient hydrolysis of corresponding peptides by patient-derived PR in comparison to the wt enzyme. This indicates a very efficient coevolution of enzyme and substrate maintaining high viral loads in vivo under constant drug pressure.

Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic Prague Czech Republic

Zobrazit více v PubMed

Adachi A, et al. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284–291 PubMed PMC

Balode D, Westman M, Kolupajeva T, Rozentale B, Albert J. 2010. Low prevalence of transmitted drug resistance among newly diagnosed HIV-1 patients in Latvia. J. Med. Virol. 82:2013–2018 PubMed

Bartonova V, et al. 2008. Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies. Antiviral Res. 78:275–277 PubMed

Betts MJ, Sternberg MJ. 1999. An analysis of conformational changes on protein-protein association: implications for predictive docking. Protein Eng. 12:271–283 PubMed

Brynda J, et al. 2004. Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex. Acta Crystallogr. D Biol. Crystallogr. 60:1943–1948 PubMed

Castro E, et al. 2010. HIV-1 drug resistance transmission networks in southwest Switzerland. AIDS Res. Hum. Retroviruses 26:1233–1238 PubMed

Cígler P, et al. 2005. From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease. Proc. Natl. Acad. Sci. U. S. A. 102:15394–15399 PubMed PMC

Cote HC, Brumme ZL, Harrigan PR. 2001. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75:589–594 PubMed PMC

Dam E, et al. 2009. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog. 5:e1000345 doi:10.1371/journal.ppat.1000345 PubMed DOI PMC

Delaugerre C, et al. 2004. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir. Ther. 9:415–421 PubMed

Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126–2132 PubMed

Frentz D, et al. 2010. Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One 5:e11505 doi:10.1371/journal.pone.0011505 PubMed DOI PMC

Grant P, et al. 2009. Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor. Clin. Infect. Dis. 48:680–682 PubMed

Ho SK, et al. 2008. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. Virology 378:272–281 PubMed PMC

Jain V, et al. 2010. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002–2009. PLoS One 5:e15510 doi:10.1371/journal.pone.0015510 PubMed DOI PMC

King NM, et al. 2004. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 78:12012–12021 PubMed PMC

Kolli M, Lastere S, Schiffer CA. 2006. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate. Virology 347:405–409 PubMed

Kozisek M, et al. 2008. Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region. J. Virol. 82:5869–5878 PubMed PMC

Lescar J, et al. 1999. Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody. Protein Sci. 8:2686–2696 PubMed PMC

Li KB. 2003. ClustalW-MPI: ClustalW analysis using distributed and parallel computing. Bioinformatics 19:1585–1586 PubMed

Little KE, Bland RM, Newell ML. 2008. Vertically acquired paediatric HIV infection: the challenges of providing comprehensive packages of care in resource-limited settings. Trop. Med. Int. Health 13:1098–1110 PubMed

Mammano F, Petit C, Clavel F. 1998. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J. Virol. 72:7632–7637 PubMed PMC

Mammano F, Trouplin V, Zennou V, Clavel F. 2000. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. 74:8524–8531 PubMed PMC

Minor W, Cymborowski M, Otwinowski Z, Chruszcz M. 2006. HKL-3000: the integration of data reduction and structure solution–from diffraction images to an initial model in minutes. Acta Crystallogr. D Biol. Crystallogr. 62:859–866 PubMed

Murshudov GN, Vagin AA, Dodson EJ. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53:240–255 PubMed

Muzammil S, Ross P, Freire E. 2003. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 42:631–638 PubMed

Myint L, et al. 2004. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antivir. Chem. Chemother. 48:444–452 PubMed PMC

Nijhuis M, et al. 2007. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med. 4:e36 doi:10.1371/journal.pmed.0040036 PubMed DOI PMC

Obermeier M, et al. 2012. HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge. Intervirology 55:102–107 PubMed

Richards AD, et al. 1990. Sensitive, soluble chromogenic substrates for HIV-1 proteinase. J. Biol. Chem. 265:7733–7736 PubMed

Sanches M, et al. 2007. Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development. J. Mol. Biol. 369:1029–1040 PubMed

Saskova KG, et al. 2008. Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir. Protein Sci. 17:1555–1564 PubMed PMC

Saskova KG, et al. 2009. Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir. J. Virol. 83:8810–8818 PubMed PMC

Shen L, et al. 2008. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14:762–766 PubMed PMC

Tebit DM, Zekeng L, Kaptue L, Kräusslich HG, Herchenröder O. 2003. Construction and characterisation of a full-length infectious molecular clone from a fast replicating, X4-tropic HIV-1 CRF02.AG primary isolate. Virology 313:645–652 PubMed

Thompson MA, et al. 2010. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304:321–333 PubMed

US Department of Health and Human Services 14 October 2011, posting date Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services, Washington, DC

Vaclavikova J, et al. 2005. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression. Acta Virol. 49:29–36 PubMed

Vagin A, Teplyakov A. 2000. An approach to multi-copy search in molecular replacement. Acta Crystallogr. D Biol. Crystallogr. 56:1622–1624 PubMed

van Maarseveen NM, et al. 2012. Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity. Retrovirology 9:29 doi:10.1186/1742-4690-9-29 PubMed DOI PMC

van Maarseveen NM, et al. 2007. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J. Infect. Dis. 195:399–409 PubMed

Velazquez-Campoy A, et al. 2003. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design. Curr. Drug Targets Infect. Disord. 3:311–328 PubMed

Wang J, Bambara RA, Demeter LM, Dykes C. 2010. Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions. J. Virol. 84:9377–9389 PubMed PMC

Weber J, et al. 2002. Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains. J. Mol. Biol. 324:739–754 PubMed

Williams JW, Morrison JF. 1979. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 63:437–467 PubMed

Youmans E, Tripathi A, Albrecht H, Gibson JJ, Duffus WA. 2011. Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009. South Med. J. 104:95–101 PubMed

Viral proteases as therapeutic targets

Precursors of Viral Proteases as Distinct Drug Targets

Zobrazit více v PubMed

GENBANK
JQ982505